Numerous G protein-coupled receptors (GPCRs) regulate multiple airway functions and play fundamental roles in normal and aberrant airway and lung physiology. Thus, GPCRs are prime candidates of targeting by disease therapeutics. The intriguing proton-sensing GPCR Ovarian cancer G-protein coupled receptor 1 (OGR1; aka GPR68) has recently been shown capable of regulating airway smooth muscle (ASM) contraction and proliferation. Although the study of OGR1 has been confounded by the fact that the proton is the presumed cognate ligand of OGR1, recent studies have begun to identify novel ligands and modulators capable of regulating the diverse signaling, and functional role of OGR1. Such studies offer hope for OGR1-targeting drugs as therapeutics for obstructive lung diseases such as asthma. Herein, we review the literature to date detailing the receptor biology and pharmacology of OGR1, receptor function in the airway, and describe the potential clinical utility of OGR1-modulating drugs.

中文翻译：

---

气道生理和疾病中的质子感应受体卵巢癌 G 蛋白偶联受体 1 (OGR1)。

许多 G 蛋白偶联受体 (GPCR) 调节多种气道功能，并在正常和异常气道和肺生理学中发挥重要作用。因此，GPCR 是疾病疗法靶向的主要候选者。有趣的质子感应 GPCR 卵巢癌 G 蛋白偶联受体 1（OGR1；又名 GPR68）最近被证明能够调节气道平滑肌 (ASM) 的收缩和增殖。虽然 OGR1 的研究因质子是 OGR1 的假定同源配体这一事实而感到困惑，但最近的研究已经开始鉴定能够调节 OGR1 的多种信号传导和功能作用的新型配体和调节剂。这些研究为 OGR1 靶向药物作为哮喘等阻塞性肺病的治疗方法提供了希望。在此处，